MannKind (MNKD) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed MannKind (MNKD) over the past year, gaining 213.9% versus a loss of 23.5%. Over five years, SLN leads with a -10.0% price change compared with -16.8% for MNKD. MannKind is the larger company by market cap ($1.24 billion vs $1.23 billion), about 1.0 times the size.
MannKind converts more of its revenue into profit, with a net margin of 1.7% versus -15851.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | SLN |
|---|---|---|
| Share price | $3.85 | $19.81 |
| Market cap | $1.24B | $1.23B |
| 1-day change | -2.53% | 0.00% |
| YTD return | -32.10% | +225.82% |
| 1-year return | -23.46% | +213.95% |
| 5-year return | -16.85% | -9.95% |
| Forward P/E | 24.44 | — |
| EPS (TTM) | $-0.24 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $348.97M | $559.00K |
| Revenue growth (YoY) | +22.23% | -98.71% |
| Net income (latest FY) | $5.86M | $-88.61M |
| Gross margin | 92.32% | 61.54% |
| Operating margin | 11.12% | -16292.84% |
| Net margin | 1.68% | -15851.88% |
| 52-week high | $6.51 | $19.87 |
| 52-week low | $2.23 | $4.19 |
| Distance from 52-week high | -40.86% | -0.28% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +116.36% | -0.30% |
| Average volume | 3.96M | 2.41M |
| Shares outstanding | 321.64M | 62.20M |
| Employees | 591 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed MNKD by 237.4 percentage points over the past year.
- MannKind is more profitable, keeping 1.7 cents of every revenue dollar as net income versus -15851.9 cents for Silence Therapeutics Plc American Depository Share.
- MannKind grew revenue faster in its latest fiscal year (+22.23% vs -98.71%).
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
MNKD vs SLN FAQ
Which is bigger, MannKind or Silence Therapeutics Plc American Depository Share?
MannKind (MNKD) is larger, with a market capitalization of $1.24B compared with $1.23B for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, MNKD or SLN?
SLN returned +213.95% over the past 12 months, compared with -23.46% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.